Radnostix, Inc. (OTC: INIS) is a radioisotope manufacturing company that produces radioisotope-focused products for medical and industrial applications. Revenue comes from transactional product sales across five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The company is headquartered in Idaho Falls, Idaho, was incorporated as a Texas corporation in 1995 (formerly International Isotopes Inc., renamed December 23, 2025), and operates manufacturing out of a single leased facility at 4137 Commerce Circle. Total revenue was $13 million in FY2025, the second-highest annual figure in company history. The Theranostics Products segment generated $6.8 million in FY2025 revenue, also the second-highest for that segment. Calibration & Reference Products accounted for approximately 33% of total revenue in FY2025 ($4,248,074), up from 25% ($3,519,216) in FY2024. The company holds the only FDA-approved generic sodium iodide I-131 ANDA manufactured in the United States, approved in February 2020. The company has never paid a cash dividend on its common stock.

Revenue model

Transactional product sales across five segments. Theranostics Products (including generic sodium iodide I-131 sold to radiopharmacy customers, plus API and radiochemical forms) drove $6.8 million in FY2025 revenue. Calibration & Reference Products generated $4,248,074 in FY2025. Medical Devices segment revenue comes entirely from third-party product sales, including radiosynthesis modules distributed under a distribution and servicing agreement with Scintomics ATT (signed 2024). Fluorine Products recorded $0 in revenue in both FY2025 and FY2024.

Products and services

Generic sodium iodide I-131 (ANDA approved February 2020, the only U.S.-manufactured FDA-approved generic); Theranostics Products in API and radiochemical form; Cobalt Products (including cobalt-60 sourced from the Advanced Test Reactor at Idaho National Laboratory); Calibration & Reference Products including PET-focused calibration sources; Medical Devices including radiosynthesis modules (Scintomics ATT line) and lung ventilation products (Swirler Radioaerosol System, Tru-Fit mouthpiece, Xenon System products acquired from AMICI, Inc., under development as of FY2025); Fluorine Products (no revenue since at least 2013).

Customers and end markets

Radiopharmacy customers who manufacture patient-specific capsules and sell to clinicians in the U.S. (sodium iodide I-131). End markets include thyroid disease treatment (hyperthyroidism, thyroid carcinoma), nuclear medicine calibration, theranostics, and medical imaging. Industrial customers for radiochemicals. The company ships sodium iodide I-131 to all 50 U.S. states and periodically to overseas locations.

Value-chain role

Upstream radioisotope manufacturer and supplier. Manufactures and ships bulk radioactive drug product (sodium iodide I-131) to radiopharmacy intermediaries, who then compound and distribute patient-specific doses to clinicians. Also acts as a distributor of third-party medical devices (Scintomics ATT radiosynthesis modules) in the Medical Devices segment. Relies on the Advanced Test Reactor (ATR) at Idaho National Laboratory for cobalt-60 and medical isotope supply.

Geographic exposure

Primarily United States. Manufacturing operations in Idaho Falls, Idaho. TI Services subsidiary leases office space in Ohio. Sodium iodide I-131 shipped to all 50 U.S. states and periodically to some overseas locations. Conditional title held on 640 acres in Lea County, New Mexico (proposed de-conversion facility, on hold since 2013).

Source: SEC 10-K, filed 2026-03-31

Industry: Industrial Instruments For Measurement, Display, and Control Peers: BNB Plus Corp PRESSURE BIOSCIENCES INC Niagen Bioscience Inc Telesis Bio Inc. Reflect Scientific Inc Standard BioTools Inc IsoPlexis Corp Miromatrix Medical Inc. Atlantic International Corp Thermo Fisher Scientific Inc